Qubit Pharmaceuticals and Singapore’s CQT Launch Strategic Quantum Computing Alliance for Molecular Discovery

Qubit Pharmaceuticals and Singapore’s CQT partner to develop quantum algorithms that improve the accuracy and speed of molecular drug discovery.

By: AXL Media

Published: May 1, 2026, 4:36 AM EDT

Source: Information for this report was sourced from EurekAlert

A Transcontinental Alliance for Quantum Chemistry

Qubit Pharmaceuticals and the Centre for Quantum Technologies in Singapore have formalized a two-year research agreement aimed at revolutionizing molecular discovery through specialized quantum algorithms. This partnership bridges the Parisian firm’s proficiency in chemical sampling with the technical infrastructure of one of Asia’s premier research institutions. By combining their respective strengths in circuit design and experimental implementation, the organizations intend to bridge the gap between abstract quantum theory and the tangible requirements of modern drug development pipelines.

Bridging the Gap Between Theory and Hardware

According to Robert Marino, CEO of Qubit Pharmaceuticals, while the theoretical framework for quantum algorithms in chemistry has existed for many decades, practical deployments remain exceedingly rare in the industry. The initiative focuses on moving these constructs into a functional space where they can serve as reliable computational instruments. This transition is facilitated by the rapid evolution of quantum hardware, which the joint team seeks to match through the development of equally advanced software solutions and circuit architectures.

Targeting Critical Computational Bottlenecks

The research team is specifically focusing on high-impact methodologies such as variational quantum eigensolvers, quantum phase estimation, and quantum Markov Chain Monte Carlo sampling. These tools are designed to address the most significant hurdles in drug discovery, including the need for extreme precision in predicting drug properties and the demand for efficient molecular simulations. Jean-Philip Piquemal, Chief Scientific Officer at Qubit Pharmaceuticals, noted that modeling chemistry with higher fidelity allows researchers to make better decisions much earlier in the development process.